Radu Hagau, MD
Cardiovascular Disease · Mason City, IANPI 1073742144
Payments from drug & device makers
What this record shows
21 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 32.9% of the total. Reporting peaked in 2021 at $1,922 and has fallen 68.1% since, to $613 in 2025.
Across 69 payments — averaging $44.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Siemens Medical Solutions USA, Inc.$1K
- GE HealthCare$908
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$166
- Edwards Lifesciences$133
- Novartis$107
- AstraZeneca$103
- plus $654 from 15 others
What the payments were for
- Travel & lodging$1,81059%
- Food & beverage$1,27541%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Siemens Medical Solutions USA, Inc. | 9 | $1,014 |
| GE HealthCare | 5 | $908 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $166 |
| Edwards Lifesciences | 2 | $133 |
| Novartis | 6 | $107 |
| AstraZeneca | 6 | $103 |
| Abbott | 4 | $93 |
| Boehringer Ingelheim | 5 | $85 |
| Atricure, Inc. | 1 | $77 |
| Pfizer | 3 | $62 |
| Bridgebio Pharma, Inc. | 3 | $55 |
| Irhythm Technologies, Inc. | 1 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Merck | 2 | $35 |
| Johnson & Johnson | 2 | $33 |
| Boston Scientific | 1 | $31 |
| Bayer | 2 | $31 |
| Heartflow, Inc. | 1 | $22 |
| Teleflex LLC | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOMATOM X.cite$889
How this compares
$3,085 in reported general payments places this provider in the 70th percentile of 142 cardiovascular disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 218 | $214,180 |
| XareltoRivaroxaban | 45 | $45,134 |
| BrilintaTicagrelor | 14 | $15,715 |
| Praluent PenAlirocumab | 28 | $15,539 |
| JardianceEmpagliflozin | 13 | $11,255 |
| Metoprolol Succinate | 640 | $10,098 |
| Repatha SureclickEvolocumab | 16 | $8,861 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 281 | $4,633 |
| Atorvastatin Calcium | 434 | $3,925 |
| Dofetilide | 20 | $3,794 |
| Rosuvastatin Calcium | 275 | $3,598 |
| Torsemide | 212 | $3,412 |
| Ranolazine ErRanolazine | 18 | $3,025 |
| ClopidogrelClopidogrel Bisulfate | 191 | $2,337 |
| Amiodarone Hcl | 37 | $1,673 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $62 | $214,180218 claims |
| Johnson & JohnsonXarelto | $33 | $45,13445 claims |
| AstraZenecaBrilinta | $103 | $15,71514 claims |
| Boehringer IngelheimJardiance | $85 | $11,25513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 142 cardiovascular disease providers in Iowa.
Other cardiovascular disease in Mason City
- Sepideh DarbandiMason City$9K
- Noor SubahMason City$8K
- Tauseef AkhtarMason City$8K
- Michael SpoonerMason City$7K
- Brett CarlsonMason City$2K
- Brian OlshanskyIowa City$219K
- Troy HounshellWest Des Moines$164K
- Enrico MartinWest Des Moines$113K
- Gursukhman Deep SidhuDavenport$60K
- Suzanne FeigofskyWest Des Moines$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.